Flaherty, Hansen of Colliers M&G lease 19,711 s/f to Acceleron Pharma
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone, muscle, red blood cells and vasculature, has executed a new 19,711 s/f lease for biotechnology laboratory space at 12 Emily St. Acceleron Pharma currently occupies a total of 75,000 s/f at 128 & 149 Sidney St., and will expand its presence to 12 Emily St. this month.
Colliers Meredith & Grew's Joe Flaherty and Tucker Hansen represented Acceleron Pharma in the transaction. The landlord, the Mass. Institute of Technology, represented itself, with John McQuaid, senior real estate officer, and Patrick Rowe, senior investment associate, handling the negotiations for the Institute.
12 Emily St. is a two-story, 30,000 s/f flexible office/research and development building. Located two blocks from University Park at M.I.T. and in close proximity to the M.I.T. campus, 12 Emily St. is ideally situated within the city's thriving biotechnology community.
NEREJ’s 2026 Mid Year Review Spotlight is underway. This special section will feature perspectives from across commercial real estate as firms reflect on the first half of the year and discuss the trends, challenges, and opportunities shaping the months ahead.
The Boston industrial market entered mid-2025 in a bifurcated state. Large-block vacancy remains elevated, while shallow-bay along the 495/128 corridor continues to prove resilient. Fieldstone’s focus on this geography positions us squarely in the middle of a renewal-driven, supply-constrained
As we enter the spring of 2026, the Rhode Island industrial real estate market stands on stable footing, following several years of resilience fueled by constrained supply, steady demand, and dynamic economic conditions.
Southern New Hampshire’s industrial market has always punched above its weight. For decades, the region has attracted a mix of advanced manufacturing, beverage and food producers, logistics operators, and specialty
These are uncertain times for the home building industry. We have the threat of tariffs mixed with high interest rates and lenders nervous about the market. Every professional, whether builder, broker, or architect, asks themselves, how do we manage our business in today’s climate? We all strive not just to succeed, but